There is a strict embargo on this press release and article until the time of its scheduled publication (March 5th, 2021 at 2pm ET). The link to the article, which will go live upon publication: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0246828
The trial assesses the safety and efficacy of the IUB™ SEAD™, a disruptive treatment for AUB. In this study, 50% of the participating patients have reached the End of the Study point, demonstrating a significant reduction in bleeding, avoiding the need to undergo invasive uterine ablation procedures or even a hysterectomy
NEW YORK, March 4, 2021 /PRNewswire/ -- Vaxalto Biotherapeutics, Inc. (www.vaxalto.com), a pre-clinical stage biotechnology company focused on developing and commercializing novel engineered immunotherapeutic oncolytic viruses, and Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, have partnered to develop novel cancer immunotherapies. Mount Sinai has granted an exclusive, worldwide license to Vaxalto covering intellectual property and technology related...
NYON, Switzerland, March 4, 2021 /PRNewswire/ -- MedAlliance, the first drug-eluting balloon (DEB) company in the world to receive US Food and Drug Administration (FDA) Breakthrough Device Designation Status for a sirolimus DEB, has now been awarded breakthrough status for SELUTION SLR™, its sustained limus release DEB catheter, in the treatment of atherosclerotic lesions in native coronary arteries. This is the fourth breakthrough designation awarded to MedAlliance for its sirolimus DEB, followi...
LONDON, March 4, 2021 /PRNewswire/ -- On HPV Awareness Day, the International Papillomavirus Society is urging women to attend delayed cervical screenings and for all interrupted services to re-start as thousands continue to miss out on vital HPV care, with deadly consequences. The IPVS is also calling for global vaccine equity.
DNA Script will receive up to $9.35 million to leverage the company's novel enzymatic DNA synthesis (EDS) technology for the project
In questa collaborazione, Almirall commercializzerà la crema Wynzora® per il trattamento della psoriasi a placche in Europa e MC2 Therapeutics sarà responsabile della produzione e fornitura
LONDON, March 3, 2021 /PRNewswire/ -- The International Consortium for Health Outcomes Measurement (ICHOM) signs a multi-year agreement with Dutch health analytics company LOGEX to launch the ICHOM Global Benchmarking Platform. The collaboration will provide the healthcare community the first ever platform to benchmark patient outcomes internationally, enabling faster learning and improvements of healthcare across the globe.
SEOUL, South Korea, March 3, 2021 /PRNewswire/ -- Wellmarker Bio(www.wmbio.co) announced that on February 23, 2021 the company received approval from the Australian Therapeutic Goods Administration (TGA) for a Phase I clinical trial using WM-S1-030, a targeted anti-cancer drug for colorectal cancer and progressive cancer.
SEOUL, South Korea, March 3, 2021 /PRNewswire/ -- Seegene (KQ096530), a biotechnology company specializing in molecular diagnostics, said Monday it finished the development of the world's first-ever variant diagnostic test that can simultaneously detect COVID-19 and screen multiple virus variants, with a single multiplex real-time PCR testing. The 'Allplex™ SARS-CoV-2 Master Assay' can detect both coronavirus and its variants in the initial round of testing. It's an ideal way of screening coronav...
SEATTLE, March 3, 2021 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence in Milan, to increase capacities and implement viral vector suspension capabilities.
AUSTIN, Texas, March 2, 2021 /PRNewswire/ -- Beyond Batten Disease Foundation (BBDF) is pleased to announce an agreement with Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, to provide Zavesca® (miglustat) for the development of BBDF-101, a proprietary combination of miglustat and trehalose to treat juvenile Batten disease (CLN3). Janssen will provide drug supply for the clinical trials and Extended Access Program, and right of reference to data within the Zav...
PHILADELPHIA and OXFORD, March 2, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the c...
MUMBAI, India, March 2, 2021 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (U.S. FDA).
In seguito alla verifica da parte dell'FDA dei dati dello studio di fase II condotto negli Stati Uniti, RedHill prevede l'espansione negli Stati Uniti dello studio globale di fase II/III su Opaganib somministrato per via orale nei casi gravi di COVID-19
NUR-SULTAN, Kazakhstan, Feb. 25, 2021 /PRNewswire/ -- Astana Club, one of the most esteemed geopolitical forums for Europe and Asia, announces the latest edition of the international rating "TOP-10 Risks for Eurasia in 2021".
